<DOC>
	<DOCNO>NCT00973739</DOCNO>
	<brief_summary>The purpose study determine Lapatinib effect tumor find patient Neurofibromatosis Type 2 ( NF2 ) . NF2 condition mainly affect skin nervous system . It cause non-cancerous tumor ( know neuromas ) grow nerve around person 's body . Some sign NF2 include gradual loss hearing tumor grow skin , brain spinal cord lead complication . Lapatinib oral drug approve Food Drug Administration ( FDA ) type tumor , approve FDA treatment NF2 related tumor . The investigator know lot well tolerate , investigator know effective treat condition , therefore consider investigational medication . This study test whether Lapatinib may shrink tumor commonly find patient NF2 stop grow . This help u decide Lapatinib use treat NF2 patient future . Lapatinib drug use 10 year treat various form cancer . It study treatment tumor NF2 patient .</brief_summary>
	<brief_title>Lapatinib Study Children Adults With Neurofibromatosis Type 2 ( NF2 ) NF2-Related Tumors</brief_title>
	<detailed_description>In trial , propose assess objective response rate Lapatinib patient NF2-related tumor . Lapatinib commercially available inhibitor ErbB2 EGF . Data suggest abnormal signal via EGFR ErbB2 major contributor tumor growth progression sporadic NF2-related VS inhibition signal pathway result decreased tumor growth . Demonstrating Lapatinib produce objective response reduce tumor volume stabilize disease provide additional treatment option NF patient multiple tumor growth . For patient VS expect see ≥ 10 dB improvement PTA and/or improvement SDS , compare audiogram initiation treatment . Currently available treatment option NF2 patient multiple tumor . Depending tumor cell type , lapatinib cytostatic cytotoxic antitumor effect , recent study assess biological effect Lapatinib associate molecular pathway tumor growth patient solid tumor , correlation see tumor response pre-treatment level ( phosphor ) -ErbB2 ( phosphor ) -ERK1/2 .</detailed_description>
	<mesh_term>Neurofibromatoses</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Neurilemmoma</mesh_term>
	<mesh_term>Neuroma , Acoustic</mesh_term>
	<mesh_term>Neurofibromatosis 2</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>1 . Patients must least 4 year age . 2 . Patients must meet diagnostic criterion NF2 least one volumetrically measure NF2related brain spinal tumor radiographic evidence progression past 12 month , designate primary target OR volumetrically measurable VS ipsilateral progressive hearing loss past 12 month , designate primary target tumor . 3 . Significant hearing loss criterion enrollment . 4 . Karnofsky ( PS ) OR Lansky 50100 % ( &gt; 16 year age ) 5 . Absolute neutrophil count ≥ 1,000/mm3 g/dL 6 . Hemoglobin ≥ 8 g/dL 7 . Creatinine ≤ 1.5 time upper limit normal ( ULN ) OR correct glomerular filtration rate ≥ 70 ml/min 8 . Bilirubin ≤ 1.5 time ULN 9 . ALT ≤ 2.5 time ULN 10 . Fully recovered acute toxic effect prior chemotherapy , biological modifier radiotherapy . 11 . Steroids allow progressive symptom patient must stable dose least 1 week prior study entry . 12 . Any neurologic deficit must stable ≥ 1 week . 13 . Patients potential pregnancy impregnate partner must agree follow acceptable birth control method avoid conception . Women childbearing potential must negative pregnancy test . The antiproliferative activity experimental drug may harmful develop fetus . 14 . Normal cardiac leave ventricular ejection fraction ( LVEF ) transthoracic echocardiogram . 15 . Able provide write informed consent ( consent parent/legal guardian minor ) 1 . Patients serious concurrent infection medical illness . 2 . Neurological deficit rapidly progress . 3 . Patients pregnant breastfeeding . 4 . Antitumor therapy within 4 week prior enrollment . 5 . Radiation therapy within 2 month prior enrollment . 6 . Prior therapy agent target EGFR ErbB2 . 7 . Any surgery within 4 week prior enrollment . 8 . Significant gastrointestinal disorder ( ) 9 . Known cardiac disease 10 . Patients concurrent prior malignancy ineligible unless patient curatively treat carcinomainsitu basal cell carcinoma skin . Patients free disease ( prior malignancy ) five year eligible study . 11 . Patients receive cytochrome P450inducing anticonvulsant ( EIADs ; e.g. , phenytoin , carbamazepine , phenobarbital , primidone , oxcarbazepine ) similar agent ( e.g. , rifampin ) P450inhibiting agent ( Ketoconazole , Itraconazole , Clarithromycin , Atazanavir , Indinavir , Nefazodone , Nelfinavir , Ritonavir , Saquinavir , Telithromycin , Voriconazole )</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>NF-2</keyword>
	<keyword>NF-2 related tumor</keyword>
	<keyword>Schwannoma , Acoustic , Bilateral</keyword>
	<keyword>schwannomas</keyword>
	<keyword>Neurilemmoma cranial peripheral nerve</keyword>
	<keyword>NF2 relate benign intracranial tumor include</keyword>
	<keyword>NF2 relate meningioma</keyword>
	<keyword>NF2 relate ependymomas</keyword>
	<keyword>NF2 relate spinal neurofibroma</keyword>
	<keyword>NF2 relate glioma</keyword>
</DOC>